Welcome to our dedicated page for National Resh news (Ticker: NRC), a resource for investors and traders seeking the latest updates and insights on National Resh stock.
National Resh Corp (NRC) delivers actionable healthcare experience insights through advanced analytics and proprietary methodologies. This news hub provides investors and industry professionals with essential updates on strategic initiatives shaping patient care innovation.
Access real-time press releases covering earnings disclosures, partnership announcements, and operational developments. Our curated feed simplifies tracking NRC's progress in transforming healthcare interactions through data-driven solutions.
Discover updates on key focus areas including patient engagement metrics, employee experience enhancements, and analytics platform innovations. Content is organized chronologically for efficient monitoring of NRC's market position and industry leadership.
Bookmark this page for streamlined access to verified NRC developments. Combine our updates with Stock Titan's financial tools to analyze the company's performance in healthcare experience optimization.
National Research Corporation (NASDAQ:NRC) reported a strong Q3 2021, with total recurring contract value reaching $151.5 million. Revenue increased 13% to $37.8 million, while operating income rose 9% to $13.1 million. The company experienced a 20% growth in Voice of the Customer offerings, gaining new clients like Sharp Healthcare and UConn Health. Year-to-date revenue increased 11% to $109.7 million. However, net income saw a slight decrease to $27.8 million compared to $29 million in 2020, attributed to a higher effective tax rate.
National Research Corporation (NASDAQ:NRC) has declared a quarterly cash dividend of $0.12 per share. This dividend will be payable on October 15, 2021, to shareholders of record by the close of business on September 30, 2021. NRC has established itself as a leading provider of analytics and insights to enhance human understanding for over 40 years, showcasing its commitment to shareholder returns.
National Research Corporation reported strong Q2 2021 results, achieving a 17% revenue increase to $36.4 million and a 32% rise in operating income to $12.2 million. The total recurring contract value grew 5% to $149.8 million, driven by a 29% boost in Voice of the Customer offerings. The cash balance increased to $48.9 million. However, the effective tax rate rose to 25% from 10% in the previous year, impacting net income which reached $8.9 million, up from $7.7 million. The company focuses on organic growth and enhancing client relationships.
National Research Corporation (NASDAQ:NRC) declared a quarterly cash dividend of $0.12 per share, payable July 15, 2021. Shareholders on record by June 30, 2021 will receive this dividend. With over 40 years of experience, NRC remains a leading provider of analytics and insights aimed at enhancing human understanding.
NRC Health enhances its leadership with the appointment of Penny Wheeler, CEO of Allina Health, and Stephen Lockhart, former Chief Medical Officer of Sutter Health, to its Board of Directors, effective immediately. These seasoned executives bring extensive healthcare experience and a commitment to patient-centered care. CEO Michael Hays emphasized their potential to advance NRC Health's mission of 'Human Understanding' in healthcare. Wheeler and Lockhart expressed enthusiasm for contributing to NRC’s vision of personalized healthcare experiences, particularly for underserved communities.
FAQ
What is the current stock price of National Resh (NRC)?
What is the market cap of National Resh (NRC)?
